S

Sanofi

Global pharma company; vaccines and R&D

PMS Planning and Management Head

Full-TimeUpdated on 10/14/2026Deadline 10/19/26
No salary listed
Expert
Tokyo, Japan
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Solid knowledge of Japan's Pharmaceutical and Medical Device Act and GPSP, or meaningful hands-on experience in a GxP-regulated environment.
  • At least 5 years of experience in post-marketing surveillance and investigations, with a track record of leading end-to-end programs across multiple products or therapeutic areas.
  • Experience planning and conducting post-marketing database studies and translating research objectives into scientifically sound study designs.
  • Ability to prepare regulatory documents, study protocols, analysis plans, and scientific reports to regulatory authority standards.
  • Ability to balance regulatory requirements with scientific judgment, set direction, make decisions amid complexity, and drive accountable outcomes.
  • Ability to coordinate and communicate across functions and seniority levels, engage regulatory authorities, and align internal and global stakeholders.
  • Organizational and task management capabilities to oversee multiple complex workstreams while maintaining quality, compliance, and timelines.
  • Business-level written and verbal English communication skills.
  • Japanese fluency.
Responsibilities
  • Lead and develop a high-performing team responsible for planning, executing, and reporting post-marketing surveillance activities.
  • Design and oversee scientifically appropriate post-marketing surveillance programs, including usage surveys, database studies, and post-marketing clinical trials, tailored to product profiles and informed by clinical trial data, global risk management practices, and regulatory commitments.
  • Lead negotiations with regulatory authorities, respond to inquiries, manage re-examination application conformity inspections, and represent the team in regulatory consultations.
  • Guide the full post-marketing surveillance lifecycle, including study outline development, protocol and case report form creation, global approvals, analysis planning, clinical study report preparation, and periodic safety reporting.
  • Build and maintain partnerships with Development, Medical, Safety, Regulatory Affairs, and Commercial teams, including global stakeholders, for aligned, timely, and compliant execution.
  • Mentor and develop team members, foster continuous improvement, and modernize processes in line with evolving regulations and the external environment.
Desired Qualifications
  • Bring fresh thinking and bold proposals to how post-marketing surveillance is designed and delivered while maintaining regulatory compliance.
  • Challenge existing approaches and drive change rather than only maintaining current practices.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)